📷 Image: Wikimedia Commons / Vyacheslav Argenberg
Health
Maharashtra FDA revokes Cipla unit's licence over Reactin Plus irregularities
✍️ Livemint
🗓 28 Aug 2026, 11:02 PM
👁 2
The Maharashtra state Food and Drug Administration, led by Tukaram Mundhe, cancelled the licence of a Cipla subsidiary after finding irregularities in its Reactin Plus product.
Maharashtra's state Food and Drug Administration, headed by Commissioner Tukaram Mundhe, has formally withdrawn the manufacturing licence of a Cipla subsidiary. The decision was taken after regulators identified several non‑compliance issues linked to the nutraceutical product Reactin Plus.
Investigations revealed that the product's labelling, safety data and manufacturing records did not meet the standards prescribed under the state's drug laws. The FDA cited these irregularities as a breach of both quality‑control and consumer‑protection norms.
As a result of the licence cancellation, the Cipla unit must cease production and sales of Reactin Plus until it can demonstrate full compliance. The agency has warned that further penalties could be imposed if corrective actions are not promptly undertaken.
Cipla has not issued a public statement on the matter, but the move underscores the state's tightening oversight of dietary supplements and pharmaceutical products.
Investigations revealed that the product's labelling, safety data and manufacturing records did not meet the standards prescribed under the state's drug laws. The FDA cited these irregularities as a breach of both quality‑control and consumer‑protection norms.
As a result of the licence cancellation, the Cipla unit must cease production and sales of Reactin Plus until it can demonstrate full compliance. The agency has warned that further penalties could be imposed if corrective actions are not promptly undertaken.
Cipla has not issued a public statement on the matter, but the move underscores the state's tightening oversight of dietary supplements and pharmaceutical products.